Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.

Abstract

We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with confirmed undetectable MRD (uMRD) were randomized to placebo or ibrutinib; patients without confirmed uMRD were randomized to ibrutinib or ibrutinib plus venetoclax. We compared immune cell subsets in cryopreserved peripheral blood mononuclear cells collected at 7 timepoints with age-matched healthy donors; median changes from baseline are reported. CLL cells decreased within 3 cycles after venetoclax initiation and from Cycle 16 onwards were similar to healthy donors (